Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PWKRJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20240245795A1 Antibody Conjugate 5
|
|||||
| Synonyms |
Antibody Conjugate 5
Click to Show/Hide
|
|||||
| Organization |
HYSLINK THERAPEUTICS
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7-8
|
|||||
| Structure |
|
|||||
| Antibody Name |
trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
| Combination Type |
A-11
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 98296 | ng/ml |
Specifically, in this example, 3 mg/kg of Antibody Conjugate 5, Antibody Conjugate 6 and DS8201 were administered to rats by
tail injection.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 820770 | ng/ml*d |
Specifically, in this example, 3 mg/kg of Antibody Conjugate 5, Antibody Conjugate 6 and DS8201 were administered to rats by
tail injection.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 820770 | ng/ml*d |
Specifically, in this example, 3 mg/kg of Antibody Conjugate 5, Antibody Conjugate 6 and DS8201 were administered to rats by
tail injection.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 820770 | ng/ml*d |
Specifically, in this example, 3 mg/kg of Antibody Conjugate 5, Antibody Conjugate 6 and DS8201 were administered to rats by
tail injection.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 820770 | ng/ml*d |
Specifically, in this example, 3 mg/kg of Antibody Conjugate 5, Antibody Conjugate 6 and DS8201 were administered to rats by
tail injection.
|
[1] |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC53) | 18.5 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC8owas calculated after reading the fluorescence data.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC52) | 0.187 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC7owas calculated after reading the fluorescence data.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||